Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real‐world results from the DELIVER Naïve cohort study-Reference-Cited by-同舟云学术

Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real‐world results from the DELIVER Naïve cohort study

Published:2019-04-05 Issue:7 Volume:21 Page:1596-1605
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Bailey Timothy S.¹,Zhou Fang L.²^ORCID,Gupta Rishab A.³,Preblick Ronald⁴,Gupta Vineet E.³,Berhanu Paulos⁵,Blonde Lawrence⁶^ORCID

Affiliation:

1. AMCR Institute Escondido California

2. Department of Real World Evidence, Sanofi Bridgewater New Jersey

3. Department of Applied Intelligence, Accenture Florham Park New Jersey

4. Department of Health Economics and Value Access Sanofi, Bridgewater New Jersey

5. Department of US Medical Affairs Sanofi, Bridgewater New Jersey

6. Frank Riddick Diabetes Institute, Endocrinology Department, Ochsner Medical Center New Orleans Louisiana

Funder

Sanofi

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13693

Reference23 articles.

1. Centers for Disease Control and Prevention (CDC). National diabetes statistics report. Estimates of diabetes and its burden in the United States; 2017.http://www.diabetes.org/assets/pdfs/basics/cdc-statistics-report-2017.pdf. Accessed July 3 2018.

2. Standards of medical care in Diabetes–2019;American Diabetes Association (ADA);Diabetes Care,2019

3. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

4. Sanofi. Lantus.https://www.drugs.com/pro/lantus.html. Accessed June 7 2018.

5. Sanofi. Toujeo.https://www.drugs.com/pro/toujeo.html. Accessed June 7 2018.

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: The INITIATION study;Diabetes, Obesity and Metabolism;2024-07-29

2. Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study;Advances in Therapy;2024-03-21

3. Effectiveness and Safety of Initiation and Titration of Insulin Glargine 300 U/mL in Insulin-Naive Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antidiabetic Drug Treatment in Turkey: The EASE Study;Endocrinology Research and Practice;2024-01-05

4. The economic value of insulin glargine 300 U/mL (Gla-300) in people ≥18 years of age with type 2 diabetes mellitus: a value-based economic model from a U.S. payer perspective;Journal of Medical Economics;2023-11-11

5. Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta‐analysis;Diabetes, Obesity and Metabolism;2023-02-28